Skip to content

Pain Outcomes Comparing Yoga Versus Structured Exercise (POYSE) Trial

Pain Outcomes Comparing Yoga Versus Structured Exercise (POYSE) Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01797263
Acronym
POYSE
Enrollment
256
Registered
2013-02-22
Start date
2013-08-01
Completion date
2018-12-31
Last updated
2020-02-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fibromyalgia

Keywords

fibromyalgia, yoga, exercise, pain

Brief summary

The Pain Outcomes comparing Yoga versus Structured Exercise (POYSE) Trial is a 2-arm parallel group, randomized clinical trial to compare the effectiveness of a yoga-based intervention (YOGA) with that of a structured exercise program (SEP) for subjects with fibromyalgia. The study aims are: 1) to compare the interventions' (YOGA vs. SEP) effects on overall fibromyalgia severity at 1 month (early response), 3 months (immediate post-intervention) and at 6 and 9 months (sustained effects); 2) to compare the interventions effects on specific fibromyalgia symptoms (pain, sleep, and fatigue), functional impairment, and related outcomes (quality of life, psychological symptoms); and 3) to compare the cost-effectiveness of the interventions.

Detailed description

This study sample will include 306 Veterans with fibromyalgia. Patients will be randomized to one of two treatment arms. The YOGA arm will involve a standardized 12-week, yoga-based intervention. The yoga intervention will consist of three treatment components: 1) in-person group yoga taught by a certified yoga therapist; 2) a relaxation audio recording for home-use; and 3) a DVD recording to reinforce concepts taught during in-person yoga sessions. Patients randomized to the structured exercise program (SEP) arm will participate in a 12-week exercise program delivered in a group/class format and supervised by a fitness instructor. In addition, SEP patients will receive a DVD (for home use) describing the benefits of aerobic exercise for fibromyalgia, a one-on-one consultation session with the fitness instructor, an individualized exercise prescription, and supervised exercise sessions for 12 weeks.

Interventions

OTHERYoga

A 12-week yoga intervention modified for Veterans with fibromyalgia. Each weekly session will last approximately 75 minutes. The standardized sequence of yoga poses will be introduced to participants and the instructor will tailor them to the participant's needs and abilities. Deep breathing exercises will be taught and emphasized throughout every session. Participants will be encouraged to exercise according to their limits, rather than rigid adherence to posture techniques. The yoga intervention will be tailored to the individual. It will include low intensity, low impact modified poses adapted with pathophysiologic changes of fibromyalgia in mind. Participants will also be given a Playaway(c) device with guided relaxation exercise recorded on it and asked to listen to it three times a week to reinforce the in person yoga session content.

A 12-week group exercise session consisting of a graded aerobic exercise program. The program will start at low intensity with gradual increases in exercise intensity and duration. Each weekly session will last 75 minutes. The fitness instructor will teach participants to use a table-top ergometer at a sub-maximal level, determine baseline fitness, and develop an individualized exercise prescription. The fitness instructor will provide educational tips on exercise and selection of physical activities. Participants will be given a pedometer and heart rate monitor to track their exercise at home. They will also be given an exercise DVD to use at home.

Sponsors

VA Office of Research and Development
Lead SponsorFED

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Veterans will be eligible if they have: * Widespread Pain Index (WPI) greater than 7 and Symptom Severity Scale (SS) greater than 5 or WPI 3-6 and SS greater than 9. * Symptoms have been present at a similar level for at least 3 months * The subject does not have a disorder that would otherwise explain the pain * Moderate pain severity (pain severity score greater than 5) * No changes in fibromyalgia medications for last 4 weeks * Access to a working telephone

Design outcomes

Primary

MeasureTime frameDescription
Fibromyalgia Impact Questionnaire Revised (FIQR) Total Score3 monthThis measure will be assessed at Baseline, 1, 3, 6 and 9 months. The 3 month is the primary end point and the 6 and 9 month assessments are for sustained effect. Min:0, Max: 90. Higher Score = Worse Outcome.

Secondary

MeasureTime frameDescription
Fibromyalgia Impact Questionnaire-Revised Difficulty Subscale3 MonthThis represents a subscale of the FIQr and measures patient perceived difficulty related to fibromyalgia. Min:0, Max: 20. Higher Score = Worse Outcome.
Fibromyalgia Impact Questionnaire-Revised Impact Subscale3 MonthThis is a subscale of the FIQr and measures the overall impact of fibromyalgia symptoms. Min:0, Max: 100. Higher Score = Worse Outcome.
Fibromyalgia Impact Questionnaire Revised Symptoms Subscale3 MonthThis subscale of the FIQr provides an overall fibromyalgia symptom score. Min:0, Max: 100. Higher Score = Worse Outcome
Brief Pain Inventory (BPI) Severity Subscale3 monthis an 11-item, multidimensional pain measurement tool with demonstrated reliability in patients with arthritis as well as other pain conditions. The BPI rates the intensity of pain as well as the interference of pain with mood, physical activity, work, social activity, relations with others, sleep, and enjoyment of life.Min:0, Max: 40. Higher Score = Worse Outcome.
PHQ-9 for Depression3 Monthwill be used to assess depression severity. Several studies have validated the PHQ-9 as a diagnostic measure with excellent psychometric properties. Internal consistency has consistently been shown to be high (Cronbach's alpha \> 0.80) and test-retest assessment showed the PHQ-9 to be a responsive and reliable measure of depression treatment outcomes. Min:0, Max: 27. Higher Score = Worse Outcome.
GAD-7 Anxiety Scale3 MonthThis 7-item scale represent a measure of anxiety symptom severity and provides a score from 0 to 21 with higher scores representing more severe anxiety
PTSD Checklist of Symptoms3 MonthThis 17-item scale assess PTSD symptom severity and provides a severity score; with higher scores representing more severe PTSD. Min: 0, Max: 85 with higher scores representing more severity.
SF-12 Mental Score (Health-related Quality of Life)3 MonthThe SF-12 is a well-validate measure of health-related quality of life; providing a physical and mental health component summary score. Min:0, Max: 100. Higher Score = Worse Outcome.
Multi-dimensional Fatigue Inventory3 MonthThis scale assesses overall fatigue and has been well-validated and used in other fibromyalgia trials. Min:0, Max: 100. Higher Score = Worse Outcome.
MOS Sleep Scale - Problems Index3 MonthThis scale assesses different aspects of sleep quality and provides an overall index with higher scores representing more severe sleep problems. Min:0, Max: 100. Higher Score = Worse Outcome.
Pain Catastrophizing Scale3 MonthThis 13-item scale assesses pain catastrophizing which has been found to be a predictor of poor treatment response. Min: 0. Max: 52. Higher Score = Worse Outcome.
Arthritis Self-efficacy Scale3 MonthThis scale has been well-validated to assess self-efficacy or confidence in a person's ability to complete a task. Min: 0, Max: 60. Higher score represents improvement.
SF-12 Physical Score (Health-related Quality of Life)3 MonthThe SF-12 is a well-validate measure of health-related quality of life; providing a physical and mental health component summary score. Min:0, Max: 100. Higher Score = Worse Outcome.

Countries

United States

Participant flow

Participants by arm

ArmCount
Yoga
A 12-week yoga intervention modified for Veterans with fibromyalgia. Each weekly session will last approximately 75 minutes. The standardized sequence of yoga poses will be introduced to participants and the instructor will tailor them to the participant's needs and abilities. Deep breathing exercises will be taught and emphasized throughout every session. Participants will be encouraged to exercise according to their limits, rather than rigid adherence to posture techniques. The yoga intervention will be tailored to the individual. Participants will also be given a Playaway(c) device with guided relaxation exercise recorded on it and asked to listen to it three times a week to reinforce the in person yoga session content.
129
Structured Exercise
A 12-week group exercise session consisting of a graded aerobic exercise program. The program will start at low intensity with gradual increases in exercise intensity and duration. Each weekly session will last 75 minutes. The fitness instructor will teach participants to use a table-top ergometer at a sub-maximal level, determine baseline fitness, and develop an individualized exercise prescription. The fitness instructor will provide educational tips on exercise and selection of physical activities. Participants will be given a pedometer and heart rate monitor to track their exercise at home. They will also be given an exercise DVD to use at home.
127
Total256

Withdrawals & dropouts

PeriodReasonFG000FG001
Overall StudyDeath10
Overall StudyLost to Follow-up1515
Overall StudyWithdrawal by Subject2125

Baseline characteristics

CharacteristicYogaTotalStructured Exercise
Age, Continuous57.9 years
STANDARD_DEVIATION 10.8
57.2 years
STANDARD_DEVIATION 10.9
56.4 years
STANDARD_DEVIATION 11
Arthritis self-efficacy scale33.4 units on a scale
STANDARD_DEVIATION 12.5
33.3 units on a scale
STANDARD_DEVIATION 12.8
33.3 units on a scale
STANDARD_DEVIATION 13.2
Brief Pain Inventory Pain Severity6.6 units on a scale
STANDARD_DEVIATION 1.6
6.7 units on a scale
STANDARD_DEVIATION 1.6
6.8 units on a scale
STANDARD_DEVIATION 1.6
Employment Status
Employed
43 Participants83 Participants40 Participants
Employment Status
Other
7 Participants23 Participants16 Participants
Employment Status
Retired
43 Participants81 Participants38 Participants
Employment Status
Unable to work
36 Participants69 Participants33 Participants
Fibromyalgia Impact Questionnaire-Revised Difficulty subscale12.7 units on a scale
STANDARD_DEVIATION 6.8
12.7 units on a scale
STANDARD_DEVIATION 6.6
12.7 units on a scale
STANDARD_DEVIATION 6.5
Fibromyalgia Impact Questionnaire-Revised Impact subscale10.2 units on a scale
STANDARD_DEVIATION 6.1
10.0 units on a scale
STANDARD_DEVIATION 5.9
9.8 units on a scale
STANDARD_DEVIATION 5.8
Fibromyalgia Impact Questionnaire Revised Symptoms subscale28.1 units on a scale
STANDARD_DEVIATION 7.4
27.9 units on a scale
STANDARD_DEVIATION 7.8
27.7 units on a scale
STANDARD_DEVIATION 8.1
Fibromyalgia Impact Questionnaire-Revised Total51.0 units on a scale
STANDARD_DEVIATION 17.4
50.4 units on a scale
STANDARD_DEVIATION 17.4
50.1 units on a scale
STANDARD_DEVIATION 17.5
GAD-7 Anxiety Scale8.0 units on a scale
STANDARD_DEVIATION 5.9
7.9 units on a scale
STANDARD_DEVIATION 5.6
7.7 units on a scale
STANDARD_DEVIATION 5.3
Income comfort level
Comfortable
60 Participants117 Participants57 Participants
Income comfort level
Just enough
47 Participants93 Participants46 Participants
Income comfort level
Not enough
19 Participants42 Participants23 Participants
Income comfort level
Refused to answer/missing
3 Participants4 Participants1 Participants
Marital Status
Divorced/separated
34 Participants80 Participants46 Participants
Marital Status
Married/unmarried couple
76 Participants142 Participants66 Participants
Marital Status
Widowed/never married
19 Participants34 Participants15 Participants
MOS Sleep Scale - problems index47.0 units on a scale
STANDARD_DEVIATION 11.3
46.8 units on a scale
STANDARD_DEVIATION 10.2
46.5 units on a scale
STANDARD_DEVIATION 8.9
Multi-dimensional fatigue inventory60.2 units on a scale
STANDARD_DEVIATION 22
59.6 units on a scale
STANDARD_DEVIATION 21.9
59.0 units on a scale
STANDARD_DEVIATION 21.9
Pain catastrophizing scale23.3 units on a scale
STANDARD_DEVIATION 13.7
23.7 units on a scale
STANDARD_DEVIATION 13.4
24.0 units on a scale
STANDARD_DEVIATION 13.1
Patient Health Questionnaire-9 (PHQ-9) Depression Scale11.5 units on a scale
STANDARD_DEVIATION 6.2
11.5 units on a scale
STANDARD_DEVIATION 6.2
11.4 units on a scale
STANDARD_DEVIATION 6.3
PTSD Checklist of symptoms51.5 units on a scale
STANDARD_DEVIATION 15.4
52.1 units on a scale
STANDARD_DEVIATION 14.9
52.6 units on a scale
STANDARD_DEVIATION 14.4
Race (NIH/OMB)
American Indian or Alaska Native
1 Participants3 Participants2 Participants
Race (NIH/OMB)
Asian
1 Participants1 Participants0 Participants
Race (NIH/OMB)
Black or African American
47 Participants94 Participants47 Participants
Race (NIH/OMB)
More than one race
7 Participants14 Participants7 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
5 Participants7 Participants2 Participants
Race (NIH/OMB)
White
68 Participants137 Participants69 Participants
Sex: Female, Male
Female
41 Participants80 Participants39 Participants
Sex: Female, Male
Male
88 Participants176 Participants88 Participants
SF-12 Mental Score (health-related quality of life)44.9 units on a scale
STANDARD_DEVIATION 9.5
44.2 units on a scale
STANDARD_DEVIATION 9.5
43.7 units on a scale
STANDARD_DEVIATION 9.4
SF-12 Physical Score (health-related quality of life)23.3 units on a scale
STANDARD_DEVIATION 13.7
23.7 units on a scale
STANDARD_DEVIATION 16.2
24.0 units on a scale
STANDARD_DEVIATION 18.6

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
1 / 1290 / 127
other
Total, other adverse events
26 / 12929 / 127
serious
Total, serious adverse events
2 / 1294 / 127

Outcome results

Primary

Fibromyalgia Impact Questionnaire Revised (FIQR) Total Score

This measure will be assessed at Baseline, 1, 3, 6 and 9 months. The 3 month is the primary end point and the 6 and 9 month assessments are for sustained effect. Min:0, Max: 90. Higher Score = Worse Outcome.

Time frame: 3 month

ArmMeasureValue (MEAN)Dispersion
YogaFibromyalgia Impact Questionnaire Revised (FIQR) Total Score41.5 units on a scaleStandard Deviation 19.3
Structured ExerciseFibromyalgia Impact Questionnaire Revised (FIQR) Total Score42.2 units on a scaleStandard Deviation 20.6
Secondary

Arthritis Self-efficacy Scale

This scale has been well-validated to assess self-efficacy or confidence in a person's ability to complete a task. Min: 0, Max: 60. Higher score represents improvement.

Time frame: 3 Month

Population: A small number of participants opted to not complete this Outcome measure, causing a discrepancy between this module and the flow module.

ArmMeasureValue (MEAN)Dispersion
YogaArthritis Self-efficacy Scale37.2 units on a scaleStandard Deviation 12.2
Structured ExerciseArthritis Self-efficacy Scale37.0 units on a scaleStandard Deviation 14.4
Secondary

Brief Pain Inventory (BPI) Severity Subscale

is an 11-item, multidimensional pain measurement tool with demonstrated reliability in patients with arthritis as well as other pain conditions. The BPI rates the intensity of pain as well as the interference of pain with mood, physical activity, work, social activity, relations with others, sleep, and enjoyment of life.Min:0, Max: 40. Higher Score = Worse Outcome.

Time frame: 3 month

ArmMeasureValue (MEAN)Dispersion
YogaBrief Pain Inventory (BPI) Severity Subscale5.6 units on a scaleStandard Deviation 1.9
Structured ExerciseBrief Pain Inventory (BPI) Severity Subscale5.9 units on a scaleStandard Deviation 2.3
Secondary

Fibromyalgia Impact Questionnaire-Revised Difficulty Subscale

This represents a subscale of the FIQr and measures patient perceived difficulty related to fibromyalgia. Min:0, Max: 20. Higher Score = Worse Outcome.

Time frame: 3 Month

ArmMeasureValue (MEAN)Dispersion
YogaFibromyalgia Impact Questionnaire-Revised Difficulty Subscale10.8 units on a scaleStandard Deviation 7.2
Structured ExerciseFibromyalgia Impact Questionnaire-Revised Difficulty Subscale10.5 units on a scaleStandard Deviation 6.9
Secondary

Fibromyalgia Impact Questionnaire-Revised Impact Subscale

This is a subscale of the FIQr and measures the overall impact of fibromyalgia symptoms. Min:0, Max: 100. Higher Score = Worse Outcome.

Time frame: 3 Month

ArmMeasureValue (MEAN)Dispersion
YogaFibromyalgia Impact Questionnaire-Revised Impact Subscale7.3 units on a scaleStandard Deviation 5.7
Structured ExerciseFibromyalgia Impact Questionnaire-Revised Impact Subscale7.9 units on a scaleStandard Deviation 6.2
Secondary

Fibromyalgia Impact Questionnaire Revised Symptoms Subscale

This subscale of the FIQr provides an overall fibromyalgia symptom score. Min:0, Max: 100. Higher Score = Worse Outcome

Time frame: 3 Month

ArmMeasureValue (MEAN)Dispersion
YogaFibromyalgia Impact Questionnaire Revised Symptoms Subscale23.5 units on a scaleStandard Deviation 8.9
Structured ExerciseFibromyalgia Impact Questionnaire Revised Symptoms Subscale23.8 units on a scaleStandard Deviation 9.7
Secondary

GAD-7 Anxiety Scale

This 7-item scale represent a measure of anxiety symptom severity and provides a score from 0 to 21 with higher scores representing more severe anxiety

Time frame: 3 Month

Population: A small number of participants opted to not complete this Outcome measure, causing a discrepancy between this module and the flow module.

ArmMeasureValue (MEAN)Dispersion
YogaGAD-7 Anxiety Scale6.5 units on a scaleStandard Deviation 5.7
Structured ExerciseGAD-7 Anxiety Scale6.6 units on a scaleStandard Deviation 5.4
Secondary

MOS Sleep Scale - Problems Index

This scale assesses different aspects of sleep quality and provides an overall index with higher scores representing more severe sleep problems. Min:0, Max: 100. Higher Score = Worse Outcome.

Time frame: 3 Month

Population: A small number of participants opted to not complete this Outcome measure, causing a discrepancy between this module and the flow module.

ArmMeasureValue (MEAN)Dispersion
YogaMOS Sleep Scale - Problems Index48.5 units on a scaleStandard Deviation 10.4
Structured ExerciseMOS Sleep Scale - Problems Index44.8 units on a scaleStandard Deviation 9.6
Secondary

Multi-dimensional Fatigue Inventory

This scale assesses overall fatigue and has been well-validated and used in other fibromyalgia trials. Min:0, Max: 100. Higher Score = Worse Outcome.

Time frame: 3 Month

Population: A small number of participants opted to not complete this Outcome measure, causing a discrepancy between this module and the flow module.

ArmMeasureValue (MEAN)Dispersion
YogaMulti-dimensional Fatigue Inventory49.2 units on a scaleStandard Deviation 24.6
Structured ExerciseMulti-dimensional Fatigue Inventory51.4 units on a scaleStandard Deviation 26.3
Secondary

Pain Catastrophizing Scale

This 13-item scale assesses pain catastrophizing which has been found to be a predictor of poor treatment response. Min: 0. Max: 52. Higher Score = Worse Outcome.

Time frame: 3 Month

Population: A small number of participants opted to not complete this Outcome measure, causing a discrepancy between this module and the flow module.

ArmMeasureValue (MEAN)Dispersion
YogaPain Catastrophizing Scale17.8 units on a scaleStandard Deviation 12.7
Structured ExercisePain Catastrophizing Scale18.6 units on a scaleStandard Deviation 13.9
Secondary

PHQ-9 for Depression

will be used to assess depression severity. Several studies have validated the PHQ-9 as a diagnostic measure with excellent psychometric properties. Internal consistency has consistently been shown to be high (Cronbach's alpha \> 0.80) and test-retest assessment showed the PHQ-9 to be a responsive and reliable measure of depression treatment outcomes. Min:0, Max: 27. Higher Score = Worse Outcome.

Time frame: 3 Month

Population: A small number of participants opted to not complete this Outcome measure, causing a discrepancy between this module and the flow module.

ArmMeasureValue (MEAN)Dispersion
YogaPHQ-9 for Depression8.6 units on a scaleStandard Deviation 6.1
Structured ExercisePHQ-9 for Depression9.8 units on a scaleStandard Deviation 6.4
Secondary

PTSD Checklist of Symptoms

This 17-item scale assess PTSD symptom severity and provides a severity score; with higher scores representing more severe PTSD. Min: 0, Max: 85 with higher scores representing more severity.

Time frame: 3 Month

Population: This measure was completed in those participants who screened positive for PTSD

ArmMeasureValue (MEAN)Dispersion
YogaPTSD Checklist of Symptoms48.3 units on a scaleStandard Deviation 14.7
Structured ExercisePTSD Checklist of Symptoms49.0 units on a scaleStandard Deviation 17.4
Secondary

SF-12 Mental Score (Health-related Quality of Life)

The SF-12 is a well-validate measure of health-related quality of life; providing a physical and mental health component summary score. Min:0, Max: 100. Higher Score = Worse Outcome.

Time frame: 3 Month

Population: A small number of participants opted to not complete this Outcome measure, causing a discrepancy between this module and the flow module.

ArmMeasureValue (MEAN)Dispersion
YogaSF-12 Mental Score (Health-related Quality of Life)46.4 units on a scaleStandard Deviation 8.8
Structured ExerciseSF-12 Mental Score (Health-related Quality of Life)46.4 units on a scaleStandard Deviation 10
Secondary

SF-12 Physical Score (Health-related Quality of Life)

The SF-12 is a well-validate measure of health-related quality of life; providing a physical and mental health component summary score. Min:0, Max: 100. Higher Score = Worse Outcome.

Time frame: 3 Month

Population: A small number of participants opted to not complete this Outcome measure, causing a discrepancy between this module and the flow module.

ArmMeasureValue (MEAN)Dispersion
YogaSF-12 Physical Score (Health-related Quality of Life)17.8 units on a scaleStandard Deviation 12.7
Structured ExerciseSF-12 Physical Score (Health-related Quality of Life)18.6 units on a scaleStandard Deviation 13.9

Source: ClinicalTrials.gov · Data processed: Feb 12, 2026